Ankylosing Spondylitis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Ankylosing Spondylitis Treatment Market is Segmented by Treatment Types (Medication, Therapy, and Surgery), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD) for the above segments.

Ankylosing Spondylitis Treatment Market Size

Single User License
Team License
Corporate License
Book before:
Ankylosing Spondylitis Treatment Summary
share button
Study Period 2019 - 2029
Market Size (2024) USD 6.64 Billion
Market Size (2029) USD 9.72 Billion
CAGR (2024 - 2029) 7.75 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Ankylosing Spondylitis Treatment

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

OFF

Team License

OFF

Corporate License

OFF
Book before:

Ankylosing Spondylitis Treatment Market Analysis

The Ankylosing Spondylitis Treatment Market size is estimated at USD 6.64 billion in 2024, and is expected to reach USD 9.72 billion by 2029, growing at a CAGR of 7.75% during the forecast period (2024-2029).

The COVID-19 pandemic impacted the ankylosing spondylitis market due to disruptions in various clinical studies and supply chains. COVID-19 was more common in people with ankylosing spondylitis who were taking immunosuppressive medications. For instance, an article published in BMC Journal in January 2023 stated that an electronic medical-record management system (EMRMS) was implemented at the Taichung Veterans General Hospital (TCVGH) for patients with ankylosing spondylitis (AS). The study found that the disease activity of AS worsened after the number of COVID-19 cases increased in Taiwan.

However, people with ankylosing spondylitis managed their care through telehealth visits that were carried out virtually, which compensated for the market growth in the later phase of the pandemic. The ankylosing spondylitis market started recovering since the restrictions were lifted. The market is gradually growing due to the rising product approvals and launches by market players. The market is expected to register a stable growth rate during the forecast period.

The growth of the ankylosing spondylitis treatment market is majorly driven by an increase in the prevalence rate of the target disease and rising reimbursements by government and private organizations for the treatment.

For instance, according to a StatPearls article updated in April 2022, ankylosing spondylitis (AS) is diagnosed in people younger than 40 years, and approximately 80% of patients develop first symptoms when they are younger than 30 years old. Therefore, the high burden of AS is expected to propel the AS treatment market during the forecast period.

Furthermore, the recent advancement in therapy, growing awareness about the treatments for the disease, and the development of effective drugs are the major contributors to the growth of the market. Additionally, government initiatives and advanced healthcare infrastructure are expected to propel market growth over the forecast period. For instance, in August 2022, the National Institute for Health and Care Excellence (NICE) approved reimbursement for AbbVie's Rinvoq (upadacitinib) in the United Kingdom. Such reimbursements to reduce the economic burden of a patient undergoing treatment are expected to propel market growth.

The rising clinical trials for the development of ankylosing treatment are expected to propel the demand for treatment. For instance, a phase II clinical trial was initiated in June 2021 to assess the efficacy and safety of subcutaneous SHR-1314 in patients with Active Ankylosing Spondylitis. The trial was sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and the expected completion is in March 2024. The high number of clinical trials indicates the high demand for ankylosing spondylitis treatment during the forecast period.

Additionally, the strategic initiatives by market players such as research and development to develop innovative treatments, rising approvals, and product launches are contributing to the growth of the market. For instance, in September 2023, the United States Food and Drug Administration (FDA) provided approval to the intravenous (IV) formulation of Cosentyx by Novartis for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

Similarly, in February 2021, Affibody AB received the United States Food and Drug Administration (FDA) clearance to proceed with phase 2 trials of Izokibep (engineered protein), indicated for patients with ankylosing spondylitis, which is designed to have high potency and a long half-life. Therefore, the rising clinical trial developments to develop innovative treatment is expected to propel the market growth.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the high cost of treatment is expected to impede market growth.

Ankylosing Spondylitis Treatment Market Trends

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as a first-line drug treatment for Ankylosing Spondylitis (AS). The segment is expected to hold a significant market share owing to the high burden of AS, rising research and development leading to the development of innovative NSAIDs for the treatment. For instance, according to a Statpearls article updated in September 2022, Naproxen is FDA-approved for treating acute gout, ankylosing spondylitis, and other musculoskeletal diseases. According to various research studies, all NSAIDs were significantly more effective in reducing pain severity in AS patients. Therefore, the demand for NSAIDs is high which is expected to augment the segment growth during the forecast period.

Furthermore, the strategic initiatives that market players adopt, such as product launches, approvals, and partnerships, also contribute to the segments' growth. For instance, in April 2022, RINVOQ (upadacitinib) was approved by U.S. FDA as an oral treatment for adults with active ankylosing spondylitis, who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. RINVOQ delivered rapid and meaningful disease control across two pivotal trials.

Additionally, in December 2021, Pfizer received approval from the United States Food and Drug Administration (FDA) for tofacitinib, known as Xeljanz or Xeljanz XR, a new medication to treat ankylosing spondylitis (AS) and other disorders like rheumatoid arthritis, juvenile Idiopathic Arthritis. The approvals of innovative NSAIDs are expected to propel its demand and augment the segment's growth during the forecast period.

Ankylosing Spondylitis Treatment: Number of Ankylosing Spondylitis Clinical Trials, By Phase, Global, January 2020 - January 2023

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America is expected to hold a significant market share owing to the high prevalence of target diseases, rising product approvals and launches by market players, and rising government and private organizations reimbursements.

According to an article published in Rheumatology Therapy Journal in December 2021, the prevalence of AS in the United States was 0.2% - 0.5%. The increasing trend of the prevalence of AS in the region is expected to boost the demand for treatment, thereby accelerating market growth.

Furthermore, rising research and development by market players to develop an efficient treatment for ankylosing spondylitis treatment leading to product approvals and launches are expected to propel the market growth. For instance, in December 2021, Coherus Biosciences received the United States Food and Drug Administration (FDA) approval for its Yusimry (adalimumab). It is a tumor necrosis factor (TNF) blocker biosimilar to Humira for treating AS. Also, in July 2022, AbbVie received Health Canada approval for RINVOQ (upadacitinib, 15 mg), an oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active ankylosing spondylitis (AS). The development and approval of advanced treatments are expected to propel market growth in the region.

In addition, various government and non-profit organizations provide reimbursements or patient assistance for reducing the economic burden of patients undergoing AS treatment. For instance, the Patient Access Network (PAN) Foundation is a US-based non-profit organization that provides USD 5,200 in assistance per year to Ankylosing Spondylitis patients.

Therefore, the North American region is expected to witness growth during the forecast period due to the aforesaid factors such as the high burden of disease, rising product approvals, and launches, and high reimbursements.

Ankylosing Spondylitis Treatment Market - Growth Rate by Region

Ankylosing Spondylitis Treatment Industry Overview

The ankylosing spondylitis treatment market is moderately competitive with several players across the globe. The majority of the key player is involved in the research and manufacturing of ankylosing spondylitis therapy drugs. These market players have gained a high market share and offer a wide range of products with an extensive distribution system across the world. Some of the major key players are Novartis, Amgen, Boehringer Ingelheim International GmbH, UCB Biopharma, and AbbVie.

Ankylosing Spondylitis Treatment Market Leaders

  1. Novartis AG

  2. AbbVie Inc.

  3. Amgen Inc.

  4. Boehringer Ingelheim International GmbH

  5. UCB S.A.

*Disclaimer: Major Players sorted in no particular order

Ankylosing Spondylitis Treatment Concentration
bookmark Need More Details on Market Players and Competitors?
Download PDF

Ankylosing Spondylitis Treatment Market News

  • In August 2023, Simcere Pharmaceutical and Lynk Pharmaceuticals reported positive data from their Phase II clinical trial of LNK01001 for treating ankylosing spondylitis. Simcere and Lynk Pharmaceuticals jointly developed the LNK01001, and in March 2022, they signed a strategic agreement for the development and commercialization of LNK01001.
  • In November 2022, Australia's health regulators approved AVT02, a high-concentration and low-volume biosimilar to AbbVie's Humira (adalimumab), to treat ankylosing spondylitis (AS).
  • In July 2022, RINVOQ (upadacitinib) was approved by the European Commission as an oral treatment for adults with active non-radiographic axial spondyloarthritis.

Ankylosing Spondylitis Treatment Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Target Diseases and Rising Reimbursements for the Treatment

      2. 4.2.2 Research and Development for Effective Treatment

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 5.1 By Treatment Types

      1. 5.1.1 Medication

        1. 5.1.1.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

        2. 5.1.1.2 TNF Inhibitors

        3. 5.1.1.3 IL-17 Inhibitors

        4. 5.1.1.4 Others

      2. 5.1.2 Therapy

      3. 5.1.3 Surgery

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Novartis AG (Sandoz)

      2. 6.1.2 AbbVie Inc.

      3. 6.1.3 UCB

      4. 6.1.4 Amgen Inc.

      5. 6.1.5 Boehringer Ingelheim International GmbH

      6. 6.1.6 Celltrion Healthcare

      7. 6.1.7 Reliance Life Sciences

      8. 6.1.8 Johnson & Johnson Services, Inc.

      9. 6.1.9 Eli Lilly and Company

      10. 6.1.10 Gilead Sciences, Inc.

      11. 6.1.11 Merck & Co., Inc.

      12. 6.1.12 Pfizer Inc

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Ankylosing Spondylitis Treatment Industry Segmentation

As per the scope of the report, ankylosing spondylitis (previously known as Bechterew's disease, Bechterew syndrome, Marie Strümpell disease) is a chronic inflammatory immune-mediated condition primarily affecting the sacroiliac joints and spine. The Ankylosing Spondylitis Treatment Market is Segmented by Treatment Types (Medication (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), TNF Inhibitors, IL-17 Inhibitors, and Others), Therapy, and Surgery), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD) for the above segments.

By Treatment Types
Medication
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
TNF Inhibitors
IL-17 Inhibitors
Others
Therapy
Surgery
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
customize-icon Need A Different Region Or Segment?
Customize Now

Ankylosing Spondylitis Treatment Market Research FAQs

The Ankylosing Spondylitis Treatment Market size is expected to reach USD 6.64 billion in 2024 and grow at a CAGR of 7.75% to reach USD 9.72 billion by 2029.

In 2024, the Ankylosing Spondylitis Treatment Market size is expected to reach USD 6.64 billion.

Novartis AG, AbbVie Inc., Amgen Inc., Boehringer Ingelheim International GmbH and UCB S.A. are the major companies operating in the Ankylosing Spondylitis Treatment Market.

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Ankylosing Spondylitis Treatment Market.

In 2023, the Ankylosing Spondylitis Treatment Market size was estimated at USD 6.16 billion. The report covers the Ankylosing Spondylitis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Ankylosing Spondylitis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Global Ankylosing Spondylitis Treatment Industry Report

Statistics for the 2024 Ankylosing Spondylitis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Ankylosing Spondylitis Treatment analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Ankylosing Spondylitis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)